

An Information Service of the Division of Health Benefits

North Carolina Medicaid Pharmacy Newsletter

Number 371

October 2024

In This Issue...

Reminder of Tailored Plans Launch

Opill Without a Prescription POS Claim Coverage

Reminder: Key COVID-19 Changes Effective Oct. 1, 2024

Update from the Board of Pharmacy Regarding Hurricane Helene

Preferred Brands with Non-Preferred Generics on the Preferred Drug List (PDL)

72-Hour Emergency Supply Available for Pharmacy Prior Authorization Drugs

Checkwrite Schedule for November 2024

Published by GDIT, fiscal agent for the North Carolina Medicaid Program 800-688-66

Reminder of Tailored Plans Launch

Behavioral Health and Intellectual/Developmental Disabilities Tailored Plans are a new kind of NC Medicaid Managed Care health plan. Tailored Plans cover doctor visits, prescription drugs, and services for mental health, substance use, intellectual/developmental disabilities and traumatic brain injury in one plan. **Tailored Plans launched statewide July 1, 2024**. Approximately 200,000 beneficiaries are enrolled into Tailored Plans.

For more detailed information please access <u>Fact Sheet: What Providers Need to Know Before</u> <u>Tailored Plan Launch</u>.

Below is the Tailored Plan Pharmacy Processing information which includes the name of the plan, Pharmacy Benefit Manager (PBM) processor, Bank Identification Number (BIN), Processor Control Number (PCN) and group number for each Tailored Plan needed for pharmacy claim adjudications. The second table below provides the Tailored Plan Pharmacy Helpdesk phone number for each of the plans.

Tailored Plan Pharmacy Processing Information

| Managed Care Organization | Corresponding PBM Processor | BIN Number | PCN | Group Number(s) |
|---------------------------------|--------------------------------|---------------|----------|------------------------------|
| Alliance | Navitus | 610602 | MCD | Medicaid: TPMC NCHC: TPHC |
| Partners | CVS Caremark | 025052 | MCAIDADV | RX22AC |
| Trillium | Perform Rx | 019595 | PRX10811 | N/A |
| Vaya | Navitus | 610602 | MCD | VAYARX |

Tailored Plan Pharmacy Help Desk Contact Information

| Tailored Plan Managed Care Organization | Pharmacy Help Desk Contact Information |
|--|---|
| Alliance Health | 1-855-759-9300 |
| Partners Health Management | 1-866-453-7196 |
| Trillium Health Resources | 1-866-245-4954 |
| Vaya Health | 1-800-540-6083 |

Opill without a Prescription POS Claim Coverage

This bulletin applies to NC Medicaid Direct and NC Medicaid Managed Care.

Effective Aug. 1, 2024, NC Medicaid beneficiaries may obtain the over the counter (OTC) oral contraceptive Opill without a prescription and at no cost.

While NC Medicaid encourages establishing care with a medical home, coverage without a prescription allows Medicaid beneficiaries easy access to the product and reduces barriers such as having to make an appointment to get a prescription, needing transportation to the appointment, or even a lack of health care providers in the community. Medicaid beneficiaries will be able to get Opill from pharmacies enrolled in Medicaid who will be able to submit the Point of Sale (POS) claim for reimbursement.

Coverage for NC Medicaid Managed Care Beneficiaries

This benefit, effective Aug. 1, 2024, applies to both NC Medicaid Direct beneficiaries and NC Medicaid Managed Care members. POS claims for Opill without a prescription for all NC Medicaid beneficiaries, including NC Medicaid Direct and NC Medicaid Managed Care, should be adjudicated through NCTracks. The NC Medicaid Managed Care pharmacy benefit will not be utilized to process claims for Opill without a prescription.

NCTracks POS Claims Processor Information is below for Opill without a prescription.

| Enrollment | Claims Processor | Bin Number | PCN Number | Group Number |
|----------------------------------|------------------|------------|------------|-----------------|
| NC Medicaid Direct Beneficiaries | NCTracks | 610242 | 781640064 | N/A |
| NC Medicaid Managed Care Members | NCTracks | 610242 | 781640064 | N/A |

Please note: Opill is also covered with a prescription. For Opill with a prescription, pharmacies should continue to bill the beneficiary's managed care plan if they are enrolled in managed care.

Pharmacy Providers

For Opill to be covered without a prescription by NC Medicaid, pharmacy providers should:

- Submit a POS claim.
- Process all claims for Opill without a prescription through the NCTracks BIN, PCN and group number noted in the table above.
- Submit the claim using the pharmacy NPI as the prescriber to identify the claim is billing for "Opill without a prescription" coverage.
 The claim will be denied with a message back to pharmacy, instructing the pharmacy to "resubmit the claim using "P0" (P zero) as the edit override code."
- Resubmit the claim using Professional Service Code "P0" to override edit 07006.

*There is no State Standing Order for Opill without a prescription. The DPH Medical Director's NPI should not be submitted on the claim as the prescriber.

A \$5.00 fee will be included in the reimbursement amount paid to the pharmacy. A dispensing fee will not be paid. Beneficiaries are allowed to obtain up to a 3-month supply of Opill with each request, without a prescription, with a maximum of 13 packs per year. Opill is a progestin only contraceptive. Pharmacists should counsel beneficiaries that Opill is most effective when taken once a day at the same time each day.

Pharmacy providers are permitted and encouraged to post signage in the pharmacy to inform Medicaid beneficiaries that Opill is available at no cost, without a prescription.

Reminder: Key COVID-19 Changes Effective Oct. 1, 2024

This article applies to NC Medicaid Direct and NC Medicaid Managed Care health plans unless noted otherwise.

NC Medicaid changes related to the coverage, cost sharing and reimbursement for COVID-19 related products and treatment will take effect Oct. 1, 2024.

COVID-19 Vaccines Administration Reimbursement

The rates for COVID-19 vaccine administration will revert to the vaccine administration rates in effect for all other vaccines listed on the appropriate fee schedules. As of Oct. 1, 2024, COVID-19 vaccine administration claims with revenue code 0771 will no longer reimburse at the \$65 vaccine administration rate. For more information, review the COVID-19 Vaccines Reimbursement section of the Medicaid Bulletin, <u>SPECIAL BULLETIN COVID-19 #268: COVID-19 Testing</u>, <u>Vaccination and Counseling Coverage After the Federal Public Health Emergency</u>.

The hospital COVID-19 Vaccine MAB Admin and COVID-19 Vaccine MAB Admin fee schedules will be end-dated effective Sept. 30, 2024.

Updates to the NC Medicaid Fee Schedules will be posted to the <u>NC Medicaid Fee Schedules</u> by Oct. 1, 2024.

COVID-19 Vaccine Counseling Coverage

Additional changes beginning Oct. 1, 2024, include the end of coverage for CPT 99401 for COVID-19 vaccine counseling and the addition of coverage of "stand-alone" vaccine counseling codes G0310, G0312 and G0315.Providers should use codes G0310, G0312, and G0315 for vaccine counseling when the vaccine is not administered on the same date of service.

NC Medicaid's Early and Periodic Screening, Diagnosis and Treatment (EPSDT) CPT code 90460 for face-to-face counseling with the patient and family by the physician or qualified health care professional during the administration of a vaccine must be billed with the EP modifier. One unit is billed for each vaccine for which counseling is provided. CPT code 90460 is an immunization administration code, which includes counseling. It is not an add-on "counseling" code.

For more information on vaccine guidance for children, review the Health Check Program Guide, available on the <u>NCTracks Provider Policies</u>, <u>Manuals</u>, <u>Guidelines and Forms</u> page under Provider Policies, Manuals and Guidelines.

COVID-19 vaccines should continue to be provided to children in alignment with the Advisory Committee on Immunization Practices (ACIP) Child and Adolescent Immunization Schedule.

For more information is available in the COVID-19 Vaccine Counseling Coverage section of the Medicaid Bulletin, <u>SPECIAL BULLETIN COVID-19 #268: COVID-19 Testing, Vaccination and Counseling Coverage After the Federal Public Health Emergency.</u>

Over-the-Counter Tests for Home Use Coverage for COVID-19

Coverage for point-of-sale (POS) billing for FDA-authorized over the counter (OTC) COVID-19 tests dispensed for use by NC Medicaid beneficiaries, with full coverage, in a home setting ends Sept. 30, 2024.

The Department of Health and Human Services (NCDHHS) partnered with more than 270 local organizations statewide, called Community Access Points, to distribute free COVID-19 at-home tests in their communities. Individuals can use <u>this website to find COVID-19 home tests for</u> <u>pickup</u> near them. Individuals should call a community access point before going to pick up a test to make sure tests are available. Locations may choose to limit the number of tests available per person, per day. Individuals must be 14 years or older to pick up free at-home tests. An ID is not required.

NC Medicaid continues to cover Nucleic Acid Amplification Test (NAAT) panels (testing 3-5 targets) after Oct. 1, 2024. Providers can leverage CPT 0240U (SARS-CoV-2, influenza A, influenza B) and CPT 0241U (SARS-CoV-2, influenza A, influenza B, RSV).

Guidance on pharmacy POS coverage is available on the <u>Outpatient Pharmacy Services page</u> <u>under OTC COVID 19 Tests for Home Use</u>. The end date for this coverage (Sept. 30, 2024) was previously communicated in the Medicaid Bulletin, <u>SPECIAL BULLETIN COVID-19 #268:</u> <u>COVID-19 Testing, Vaccination and Counseling Coverage After the Federal Public Health</u> <u>Emergency.</u>

Copays and Mandatory Coverage for COVID-19 Related Treatment

NC Medicaid will reinstate cost-sharing (i.e., copays) for COVID-19 related treatments (including treatment of conditions that may seriously complicate the treatment of COVID-19) on Oct. 1, 2024. When applicable, beneficiaries will be responsible for copays for medications and outpatient specialized therapies (i.e., audiology, occupational therapy, physical therapy, respiratory therapy and speech therapy).

The limits listed in the <u>Clinical Coverage Policy 10A</u> will be enforced for individuals ages 21 and older who are seeking treatment due to COVID-19 beginning Oct. 1, 2024.

See the Medicaid Bulletin, <u>SPECIAL BULLETIN COVID-19 #259: Mandatory Coverage of</u> <u>COVID-19-Related Treatment Under the American Rescue Plan Act of 2021 (UPDATE)</u> for additional information.

COVID-19 Testing Coverage for Beneficiaries with Family Planning Medicaid

NC Medicaid will no longer cover COVID-19 testing for Family Planning (MAFDN) beneficiaries through the NC Medicaid Optional COVID-19 Testing Program after Sept. 30, 2024.

Additional information is available in the Medicaid Bulletin, <u>SPECIAL BULLETIN COVID-19</u> #156: Clinical Policy 1E-7, Family Planning Services, COVID-19 Lab Testing for MAFDN Beneficiaries.

Update from the Board of Pharmacy Regarding Hurricane Helene

DEA APPROVES USE OF BOARD RULE .1815 TO CREATE AND DISPENSE EMERGENCY REFILLS OF SCHEDULE 3, 4, AND 5 CONTROLLED SUBSTANCES.

The DEA has issued an exception letter allowing Rule .1815 to be used to create and dispense emergency refills of Schedule 3, 4, and 5 substances (found here). This exception is in effect for 30 days (until November 3, 2024), though DEA states that it will consider a further extension if emergency conditions continue to exist at that time.

REMINDER VERBAL SCHEDULE 2 PRESCRIPTIONS IN EMERGENCIES.

Pharmacists are reminded that, in the case of an "emergency situation," federal law (21 CFR 1306.11(d)) allows a pharmacist to dispense a Schedule II controlled substance upon receiving oral authorization from the prescriber, provided that: (1) the amount is limited to that adequate to treat the patient during the emergency period; (2) the prescription is immediately reduced to writing by the pharmacist; (3) if the prescriber is not known to the pharmacist, the pharmacist makes a reasonable effort to determine the oral authorization came from a DEA-registered prescriber; and (4) within 7 days, the prescriber causes a written prescription to be delivered to the dispensing pharmacist.

Preferred Brands with Non-Preferred Generics on the Preferred Drug List (PDL) *Current as of Oct. 1, 2024*

| Brand Name | Generic Name |
|------------------------------|--|
| Actiq 1600 mcg Lozenges | Fentanyl Citrate 1600 mcg Lozenges |
| Actiq 400 mcg Lozenges | Fentanyl Citrate 400 mcg Lozenges |
| Advair 100-50 Diskus | Fluticasone-Salmeterol 100-50 |
| Advair 250-50 Diskus | Fluticasone-Salmeterol 250-50 |
| Advair 500-50 Diskus | Fluticasone-Salmeterol 500-50 |
| Advair HFA 45-21 mcg Inhaler | Fluticasone-Salmeterol 45-21 HFA Inhaler |

| | 1 |
|-------------------------------|---|
| Advair HFA 115-21 mcg Inhaler | Fluticasone-Salmeterol 115-21 HFA Inhaler |
| Advair HFA 230-21 mcg Inhaler | Fluticasone-Salmeterol 230-21 HFA Inhaler |
| Alphagan P 0.1% Drops | Brimonidine P 0.1% Drops |
| Alphagan P 0.15% Drops | Brimonidine P 0.15% Drops |
| Apriso ER 0.375 Gram Capsule | Mesalamine 0.375 mg Capsule |
| Aptensio XR 10mg Capsule | Methylphenidate ER 10 mg Capsule |
| Aptensio XR 15mg Capsule | Methylphenidate ER 15 mg Capsule |
| Aptensio XR 20mg Capsule | Methylphenidate ER 20 mg Capsule |
| Aptensio XR 30mg Capsule | Methylphenidate ER 30 mg Capsule |
| Aptensio XR 40mg Capsule | Methylphenidate ER 40 mg Capsule |
| Aptensio XR 50mg Capsule | Methylphenidate ER 50 mg Capsule |
| Aptensio XR 60mg Capsule | Methylphenidate ER 60 mg Capsule |
| Banzel 200 mg Tablet | Rufinamide 200 mg Tablet |
| Banzel 400 mg Tablet | Rufinamide 400 mg Tablet |
| Bethkis 300 mg/4 ml Ampule | Tobramycin Solution 300 mg/4 ml Ampule |
| BiDil 20mg-37.5mg Tablet | Isosorbide DN 20mg/Hydralazine 37.5mg |
| Butrans 10 mcg/hr Patch | Buprenorphine 10 mcg/hr Patch |
| Butrans 15 mcg/hr Patch | Buprenorphine 15 mcg/hr Patch |
| Butrans 20 mcg/hr Patch | Buprenorphine 20 mcg/hr Patch |
| Butrans 5 mcg/hr Patch | Buprenorphine 5 mcg/hr Patch |
| Butrans 7.5 mcg/hr Patch | Buprenorphine 7.5 mcg/hr Patch |
| Cipro 10% Suspension | Ciprofloxacin 500 mg/5 ml Suspension |
| Cipro 5% Suspension | Ciprofloxacin 250 mg/5 ml Suspension |
| Combigan 0.2%-0.5% Eye Drops | Brimonidine-Timolol 0.2%-0.5% |
| Copaxone 20 mg/ml Syr | Glatiramer 20 mg/ml Syr |
| Copaxone 40 mg/ml Syr | Glatiramer 40 mg/ml Syr |
| Daytrana 10 mg/9 hr Patch | Methylphenidate 10 mg/9 hr Patch |
| Daytrana 15 mg/9 hr Patch | Methylphenidate 15 mg/9 hr Patch |
| Daytrana 20 mg/9 hr Patch | Methylphenidate 20 mg/9 hr Patch |
| Daytrana 30 mg/9 hr Patch | Methylphenidate 30 mg/9 hr Patch |
| Derma-Smoothe-FS Body Oil | Fluocinolone 0.01% Body Oil |
| Derma-Smoothe-FS Scalp Oil | Fluocinolone 0.01% Scalp Oil |

| Dermotic Otic Drops | Fluocinolone 0.01% Otic Drops |
|----------------------------|--|
| Dexilant DR 30 mg Cap | Dexlansoprazole DR 30 mg Cap |
| Dexilant DR 60 mg Cap | Dexlansoprazole DR 60 mg Cap |
| Diclegis 10-10 DR | Doxylamine Succinate/Pyridoxine HCL 10-10 DR |
| Dymista Nasal Spray | Azelastine/Fluticasone Prop Nasal Spray |
| Elidel 1% Cream | Pimecrolimus 1% Cream |
| Emflaza 18 mg tablet | Deflazacort 18 mg tablet |
| Exelon 13.3 mg/24 hr Patch | Rivastigmine 13.3 mg/24 hr Patch |
| Exelon 4.6 mg/24 hr Patch | Rivastigmine 4.6 mg/24 hr Patch |
| Exelon 9.5 mg/24 hr Patch | Rivastigmine 9.5 mg/24 hr Patch |
| Farxiga 10 mg | Dapagliflozin 10 mg |
| Farxiga 5 mg | Dapagliflozin 5 mg |
| Humalog Kwikpen Mix 75-25 | Insulin Lispro Mix 75-25 |
| Kitabis Pak 300 mg/5 ml | Tobramycin Pak 300 mg/5 ml |
| Lialda 1.2 gm Tablet | Mesalamine 1.2 gm Tablet |
| Lotemax 0.5% Eye Drops | Loteprednol 0.5% Eye Drops |
| Natroba 0.9% Topical Susp | Spinosad 0.9% Topical Susp |
| Nexium DR 10 mg Packet | Esomeprazole DR 10 mg Packet |
| Nexium DR 20 mg Packet | Esomeprazole DR 20 mg Packet |
| Nexium DR 40 mg Packet | Esomeprazole DR 40 mg Packet |
| Novolog 100 U/ml Cartridge | Insulin Aspart 100 U/ml Cartridge |
| Nuvessa Vaginal 1.3% Gel | Metronidazole Vaginal 1.3% Gel |
| Nuvigil 150 MG Tabs | Armodafinil 150 mg tabs |
| Nuvigil 200 MG Tabs | Armodafinil 200 mg tabs |
| Nuvigil 250 MG Tabs | Armodafinil 250 mg tabs |
| Nuvigil 50 MG Tabs | Armodafinil 50 mg tabs |
| Oxtellar XR 150 mg Tabs | Oxcarbazepine ER 150 mg Tabs |
| Oxtellar XR 300 mg Tabs | Oxcarbazepine ER 300 mg Tabs |
| Oxtellar XR 600 mg Tabs | Oxcarbazepine ER 600 mg Tabs |
| OxyContin ER 10mg Tablet | Oxycodone ER 10mg Tablet |
| OxyContin ER 20mg Tablet | Oxycodone ER 20mg Tablet |
| OxyContin ER 40mg Tablet | Oxycodone ER 40mg Tablet |

| OxyContin ER 80mg Tablet | Oxycodone ER 80mg Tablet |
|--------------------------------|---|
| Paxil 10 mg/5 ml | Paroxetine 10 mg/5 ml |
| Pradaxa 150 mg | Dabigatran 150 mg |
| Pradaxa 110 mg | Dabigatran 110 mg |
| Pradaxa 75 mg | Dabigatran 75 mg |
| ProAir or Ventolin HFA Inhaler | Albuterol HFA Inhaler |
| Protonix 40 mg Suspension | Pantoprazole 40 mg Suspension |
| Provigil 100 mg | Modafinil 100 mg |
| Provigil 200 mg | Modafinil 200 mg |
| Pylera Capsules | Bismuth-Metro-Tetr 140-125-125 |
| Renvela 800 mg Tablet | Sevelamer Carbonate 800 mg Tablet |
| Renvela 800 mg Packet | Sevelamer Carbonate 800 mg Packet |
| Renvela 2400 mg Packet | Sevelamer Carbonate 2400 mg Packet |
| Restasis 0.05% Eye Emulsion | Cyclosporine 0.05% Eye Emulsion |
| Retin-A 0.025% Cream | Tretinoin 0.025% Cream |
| Retin-A 0.05% Cream | Tretinoin 0.05% Cream |
| Retin-A 0.1% Cream | Tretinoin 0.1% Cream |
| Retin-A Gel 0.01% | Tretinoin Gel 0.01% |
| Retin-A Gel 0.025% | Tretinoin Gel 0.025% |
| Retin-A Micro 0.04% Gel | Tretinoin Micro 0.04% Gel |
| Retin-A Micro 0.1% Gel | Tretinoin Micro 0.1% Gel |
| Sabril 500 mg Tablet | Vigabatrin 500 mg Tablet |
| Saphris 10 mg Tab Sublingual | Asenapine 10 mg Tablet SL |
| Saphris 2.5 mg Tab Sublingual | Asenapine 2.5 mg Tablet SL |
| Saphris 5 mg Tab Sublingual | Asenapine 5 mg Tablet SL |
| Spiriva Handihaler 18 mcg Cap | Tiotropium 18 mcg Cap-Inhaler |
| Suboxone 12-3 mg Film | Buprenorphine/Naloxone 12-3 mg Film |
| Suboxone 2-0.5 mg Film | Buprenorphine/Naloxone 2-0.5 mg Film |
| Suboxone 4-1 mg Film | Buprenorphine/Naloxone 4-1 mg Film |
| Suboxone 8 mg-2 mg Film | Buprenorphine/Naloxone 8mg-2mg Film |
| Symbicort 160-4.5 mcg Inhaler | Budesonide-Formoterol 160-4.5 mcg Inhaler |
| Symbicort 80-4.5 mcg Inhaler | Budesonide-Formoterol 80-4.5 mcg Inhaler |

| Symbyax 6-25 | Olanzapine-fluoxetine 6-25 |
|------------------------------|---------------------------------|
| Tekturna 150 mg Tablet | Aliskiren 150 mg Tablet |
| Tekturna 300 mg Tablet | Aliskiren 300 mg Tablet |
| Tracleer 125 mg Tablet | Bosentan 125 mg tablet |
| Tracleer 62.5 mg Tablet | Bosentan 62.5 mg tablet |
| Transderm-Scop 1.5 mg/3 day | Scopolamine 1 mg/3 Day Patch |
| Travatan Z 0.004% Eye Drop | Travoprost 0.004% Eye Drop |
| Vagifem 10 mcg Vaginal Tab | Estradiol 10 mcg Vaginal Insert |
| Vascepa 0.5 gm Cap | Icosapent Ethyl 0.5 gm Cap |
| Vascepa 1 gm Cap | Icosapent Ethyl 1 gm Cap |
| Victoza 2-pak 18 mg/3 ml Pen | Liraglutide 18 mg/3 ml Pen |
| Vyvanse 10 mg Cap | Lisdexamfetamine 10 mg Cap |
| Vyvanse 10 mg Chew Tab | Lisdexamfetamine 10 mg Chew |
| Vyvanse 20 mg Cap | Lisdexamfetamine 20 mg Cap |
| Vyvanse 20 mg Chew Tab | Lisdexamfetamine 20 mg Chew |
| Vyvanse 30 mg Cap | Lisdexamfetamine 30 mg Cap |
| Vyvanse 30 mg Chew Tab | Lisdexamfetamine 30 mg Chew |
| Vyvanse 40 mg Cap | Lisdexamfetamine 40 mg Cap |
| Vyvanse 40 mg Chew Tab | Lisdexamfetamine 40 mg Chew |
| Vyvanse 50 mg Cap | Lisdexamfetamine 50 mg Cap |
| Vyvanse 50 mg Chew Tab | Lisdexamfetamine 50 mg Chew |
| Vyvanse 60 mg Cap | Lisdexamfetamine 60 mg Cap |
| Vyvanse 60 mg Chew Tab | Lisdexamfetamine 60 mg Chew |
| Vyvanse 70 mg Cap | Lisdexamfetamine 70 mg Cap |
| Xopenex HFA 45 mcg Inhaler | Levalbuterol HFA 45 mcg Inhaler |
| Zovirax 5% Cream | Acyclovir 5% Cream |

When a PDL class has a preferred brand with a non-preferred generic, providers requesting prior approval for the non-preferred generic should give a clinical reason why the beneficiary cannot use the brand.

72-Hour Emergency Supply Available for Pharmacy Prior Authorization Drugs

Pharmacy providers are encouraged to use the 72-hour emergency supply allowed for drugs requiring prior approval. **Federal law requires that this emergency supply be available to Medicaid beneficiaries for drugs requiring prior approval** (Social Security Act, Section 1927, <u>42 U.S.C. 1396r-8(d)(5)(B)</u>). Use of this emergency supply will ensure access to medically necessary medications.

The system will bypass the prior approval requirement if an emergency supply is indicated. Use a "3" in the Level of Service field (418-DI) to indicate that the transaction is an emergency fill.

Note: Copayments will apply. There is no limit to the number of times the emergency supply can be used.

Checkwrite Schedule for November 2024

| Electronic Cutoff Schedule | Checkwrite Date |
|----------------------------|-----------------|
| Oct. 31, 2024 | Nov. 5, 2024 |
| Nov. 7, 2024 | Nov. 13, 2024 |
| Nov. 14, 2024 | Nov. 19, 2024 |
| Nov. 21, 2024 | Nov. 26, 2024 |

POS claims must be transmitted and completed by 11:59 p.m. on the day of the electronic cutoff date to be included in the next checkwrite.

The 2024 checkwrite schedules for both NC Medicaid and DMH/DPH/ORH can be found under the Quick Links on the right side of the home page.

Angela Smith, PharmD, DHA, MHA Director of Pharmacy & Ancillary Services Division of Health Benefits, NC Medicaid N.C. Department of Health and Human Services

Sandra Terrell, MS, RN Director of Clinical Programs and Policy Division of Health Benefits N.C. Department of Health and Human Services

Jay Ludlam Deputy Secretary for NC Medicaid Division of Health Benefits Janelle White, MD, MHCM Chief Medical Officer Division of Health Benefits N.C Department of Health and Human Services

Rick Paderick, R.Ph. Pharmacy Director NCTracks GDIT

Bonnie Williams Deputy Executive Account Director NCTracks N.C. Department of Health and Human Services

GDIT

Paul Guthery

Executive Account Director NCTracks GDIT